Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.

You may also be interested in...



Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin

The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use

J&J Pharma Presents a Robust Pipeline and Outlines A New R&D Structure

In a wide-ranging presentation to Wall Street, the company highlights key new products in development and an R&D strategy built around five therapeutic areas.

J&J Pharma Presents Robust Pipeline And Outlines New R&D Structure

In a wide-ranging presentation to Wall Street, the company highlights key new products in development and an R&D strategy built around five therapeutic areas

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel